Hadiyah-Nicole Green

Hadiyah-Nicole Green

Auto-generated profile, based on publicly available information

Hadiyah-Nicole Green

Department of Surgery, Morehouse School of Medicine, 720 Westview Drive, Atlanta, GA 30310, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2019 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
XSXiaoyu Song
Xiaoyu Song
WWWanjuan Wang
Wanjuan Wang
HWHaowei Wang
Haowei Wang
XYXiao Yuan
Xiao Yuan
FYFengrui Yang
Fengrui Yang
XLXing Liu
Xing Liu
Ezrin, a membrane–cytoskeleton linker protein, plays an essential role in cell polarity establishment, cell migration, and division. Recent studies show that ezrin phosphorylation regulates breast cancer metastasis by promoting cancer cell survivor and promotes intrahepatic metastasis via cell migration. However, it was less characterized whether there are additional post-translational modifications and/or post-translational crosstalks on ezrin underlying context-dependent breast cancer cell migration and invasion. Here we show that ezrin is acetylated by p300/CBP-associated factor (PCAF) in breast cancer cells in response to CCL18 stimulation. Ezrin physically interacts with PCAF and is a cognate substrate of PCAF. The acetylation site of ezrin was mapped by mass spectrometric analyses, and dynamic acetylation of ezrin is essential for CCL18-induced breast cancer cell migration and invasion. Mechanistically, the acetylation reduced the lipid-binding activity of ezrin to ensure a robust and dynamic cycling between the plasma membrane and cytosol in response to CCL18 stimulation. Biochemical analyses show that ezrin acetylation prevents the phosphorylation of Thr567. Using atomic force microscopic measurements, our study revealed that acetylation of ezrin induced its unfolding into a dominant structure, which prevents ezrin phosphorylation at Thr567. Thus, these results present a previously undefined mechanism by which CCL18-elicited crosstalks between the acetylation and phosphorylation on ezrin control breast cancer cell migration and invasion. This suggests that targeting PCAF signaling could be a potential therapeutic strategy for combating hyperactive ezrin-driven cancer progression.

27 August 2021 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
MMMcKay Mullen
McKay Mullen
FYFengrui Yang
Fengrui Yang
JCJun Cao
Jun Cao
YCYang Cao
Yang Cao
XLXu Liu
Xu Liu
XYXuebiao Yao
Xuebiao Yao
Dear Editor,

29 September 2021 in Onco
Verified
Journal Article
Open access
PDF file
GLGee Young Lee
Gee Young Lee
MMMohamed Mubasher
Mohamed Mubasher
TMTamra S. McKenzie
Tamra S. McKenzie
NSNicole C Schmitt
Nicole C Schmitt
Sebelik MerrySebelik Merry
Sebelik Merry
HGHadiyah-Nicole Green
Hadiyah-Nicole Green
Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.